Pacific Biosciences
PACB
231 hedge funds and large institutions have $249M invested in Pacific Biosciences in 2026 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 60 increasing their positions, 70 reducing their positions, and 31 closing their positions.
71% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 31
7% more funds holding
Funds holding: 215 → 231 (+16)
9% more call options, than puts
Call options by funds: $1.17M | Put options by funds: $1.07M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.17% less ownership
Funds ownership: 66.49% → 62.31% (-4.2%)
14% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 70
33% less capital invested
Capital invested by funds: $374M → $249M (-$125M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$3.76M |
| 2 |
BlackRock
New York
|
+$3.44M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$2.12M |
| 4 |
BC
Birchview Capital
Burlington,
Vermont
|
+$1.79M |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$6.26M |
| 2 |
KOC
Koss-Olinger Consulting
Gainesville,
Florida
|
-$4.86M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.78M |
| 4 |
AG
Amiral Gestion
Paris,
France
|
-$3.21M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.84M |
PACB Hedge Fund Activity: Q1 2026 in Review
231 of the 8,181 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2026, worth a combined $249M — down 33% from $374M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new PACB positions and 31 closed out — a net gain of 22 holders — while 60 added to existing stakes and 70 trimmed.
The largest buyer was Nuveen, adding an estimated $3.76M. The largest seller was Casdin Capital, cutting an estimated $6.26M.
- 231 institutional investors held Pacific Biosciences (PACB) as of Q1 2026, up from 215 in Q4 2025.
- Funds reported $249M of Pacific Biosciences stock for Q1 2026, down 33% quarter-over-quarter.
- 53 funds opened new Pacific Biosciences positions in Q1 2026 and 31 closed out, a net change of +22 holders.
- The largest Pacific Biosciences buyer in Q1 2026 was Nuveen, an estimated $3.76M added.
- The largest Pacific Biosciences seller in Q1 2026 was Casdin Capital, an estimated $6.26M sold.
Based on aggregated 13F filings for Q1 2026.